1206550-99-3 Usage
Description
Febuxostat Descyano Impurity is an impurity of Febuxostat, a medication used for the treatment of hyperuricemia and chronic gout. It is a xanthine oxidase/xanthine dehydrogenase inhibitor, which helps in lowering serum urate levels.
Uses
Used in Pharmaceutical Industry:
Febuxostat Descyano Impurity is used as a quality control agent for the production of Febuxostat. It is important to monitor and control the levels of this impurity to ensure the safety and efficacy of the final drug product.
Used in Research and Development:
Febuxostat Descyano Impurity is used as a reference compound in the development of analytical methods and techniques for the detection and quantification of impurities in Febuxostat. This helps in improving the quality control processes and ensuring the purity of the drug.
Used in Regulatory Compliance:
Febuxostat Descyano Impurity is used in the regulatory process to establish acceptable limits for impurities in pharmaceutical products. This ensures that the drug meets the required safety and quality standards before it is approved for use in patients.
Check Digit Verification of cas no
The CAS Registry Mumber 1206550-99-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,6,5,5 and 0 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1206550-99:
(9*1)+(8*2)+(7*0)+(6*6)+(5*5)+(4*5)+(3*0)+(2*9)+(1*9)=133
133 % 10 = 3
So 1206550-99-3 is a valid CAS Registry Number.
1206550-99-3Relevant articles and documents
Design, synthesis, in silico and in vitro studies of novel 4-methylthiazole-5-carboxylic acid derivatives as potent anti-cancer agents
Kilaru, Ravendra Babu,Valasani, Koteswara Rao,Yellapu, Nanda Kumar,Osuru, Hari Prasad,Kuruva, Chandra Sekhar,Matcha, Bhaskar,Chamarthi, Naga Raju
supporting information, p. 4580 - 4585 (2015/02/19)
Since inhibitors of mucin onco proteins are potential targets for breast cancer therapy, a series of novel 4-methylthiazole-5-carboxylic acid (1) derivatives 3a-k were synthesized by the reaction of 1 with SOCl2followed by different bases/alcohols in the presence of triethylamine. Once synthesized and characterized, their binding modes with MUC1 were studied by molecular docking analysis using Aruglab 4.0.1 and QSAR properties were determined using HyperChem. All synthesized compounds were screened for in vitro anti-breast cancer activity against MDA-MB-231 breast adenocarcinoma cell lines by Trypan-blue cell viability assay and MTT methods. Compounds 1, 3b, 3d, 3e, 3i and 3f showed good anti-breast cancer activity. Since 1 and 3d exhibited high potent activity against MDA-MB-231 cell lines, they show could be effective mucin onco protein inhibitors.
